LOCALLY RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for LOCALLY RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new LOCALLY RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for LOCALLY RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy targets tough cancers using biomarker clues
Disease control Recruiting nowThis study tests two drugs, cabozantinib and nivolumab, in 150 people with advanced melanoma or head and neck cancer that hasn't responded to prior immunotherapy. The goal is to see if the combination shrinks tumors and how quickly doctors can use tumor biomarkers to sort patient…
Matched conditions: LOCALLY RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:43 UTC
-
Could a blood pressure pill boost cancer treatment? new trial combines three therapies for head and neck cancer
Disease control Recruiting nowThis early-phase trial tests whether adding a common blood pressure drug (losartan) to immunotherapy (pembrolizumab) and precise radiation (SBRT) is safe and effective for people with head and neck cancer that has returned or spread. About 24 adults whose cancer cannot be surgica…
Matched conditions: LOCALLY RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: University of California, Davis • Aim: Disease control
Last updated May 17, 2026 02:41 UTC
-
New combo therapy aims to fight stubborn head and neck cancers
Disease control Recruiting nowThis early-phase trial is for people with head and neck cancer that didn't go away or came back after treatment. Researchers are testing whether giving immunotherapy (pembrolizumab) and radiation before and during surgery can kill more cancer cells. The main goal is to find out w…
Matched conditions: LOCALLY RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated May 06, 2026 16:03 UTC
-
New combo therapy aims to boost survival in returning head and neck cancer
Disease control Recruiting nowThis study tests whether adding chemotherapy or a chemo-immunotherapy combination before standard salvage surgery helps people with a specific type of head and neck cancer that has come back or persisted. About 180 adults with PD-L1 positive cancer will be randomly assigned to on…
Matched conditions: LOCALLY RECURRENT HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC